BiotechTube

NS-050/NCNP-03 + Placebo

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Duchenne Muscular Dystrophy

Conditions

Duchenne Muscular Dystrophy

Trial Timeline

Sep 18, 2024 → May 1, 2027

NCT ID
NCT06053814

About NS-050/NCNP-03 + Placebo

NS-050/NCNP-03 + Placebo is a phase 1/2 stage product being developed by Nippon Shinyaku for Duchenne Muscular Dystrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06053814. Target conditions include Duchenne Muscular Dystrophy.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06053814Phase 1/2Recruiting

Competing Products

20 competing products in Duchenne Muscular Dystrophy

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
33
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
33
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
33
Tadalafil + PlaceboEli LillyPhase 3
77
DS-5141bDaiichi SankyoPhase 2
52
DS-5141bDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
41
NS-065/NCNP-01Nippon ShinyakuPhase 2
52
Viltolarsen + PlaceboNippon ShinyakuPhase 3
77
ViltolarsenNippon ShinyakuPhase 2
52
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
52
NS-065/NCNP-01Nippon ShinyakuPhase 1
33
NS-089/NCNP-02Nippon ShinyakuPhase 2
52
ViltolarsenNippon ShinyakuPhase 3
77
NS-089/NCNP-02Nippon ShinyakuPhase 1/2
41
NS-065/NCNP-01 + PlaceboNippon ShinyakuPhase 2
52
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wkMerckPhase 2
52
ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)MerckPhase 2
52
SatralizumabRochePhase 2
52

Other Products from Nippon Shinyaku

Viltolarsen + PlaceboPhase 3
77
ViltolarsenPhase 3
77
NS-065/NCNP-01Phase 2
52
NS-863 Low Dose + NS-863 High Dose + NS-863 PlaceboPhase 2
52
ViltolarsenPhase 2
52